MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
September 06 2023 - 8:05AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, today announced the
appointment of Ali Soleymannezhad as Executive Vice President of
Bioprocessing, effective August 21, 2023.
Mr. Soleymannezhad will lead global product
development and marketing strategy for MaxCyte’s bioprocessing
business. The bioprocessing business is anchored by the STx and VLx
platforms supporting biotherapeutic research, development and
manufacturing using transient expression to produce complex
proteins, vaccines and biologics at scale.
“With his commercial background, strategic
insight and demonstrated commitment to strong financial
performance, Ali will be a great addition to our executive
leadership team,” said Doug Doerfler, President and CEO of
MaxCyte. “Ali’s diverse experience will help build upon
the initial success we have had with the VLx in our early access
program. With Ali’s help, we look forward to expanded engagement
with early access customers and developing new customer
relationships to deliver a large-scale transfection solution that
addresses the current bottlenecks in the cell bioprocessing
market.”
Mr. Soleymannezhad brings almost 20 years of
technical, sales and marketing expertise in biomanufacturing,
bioprocessing and bioanalysis to his new role. Most recently, he
served as Executive Vice President for the Separations and
Purification business at Tosoh Bioscience overseeing a team of 140
employees across four global manufacturing, development, and
commercial sites. During his tenure at Tosoh, Mr. Soleymannezhad
was also Vice President of Global Marketing and Business
Development and Director of Sales and Marketing Americas and served
on the board of Semba Biosciences. Mr. Soleymannezhad received a
Master of Business Administration in finance from Jones Graduate
School of Business at Rice University in Texas after completing his
Master and Bachelor of Chemical Engineering at University of
Western Ontario’s Faculty of Engineering in Canada.
“As someone who understands the needs and
expectations of life science customers, one of my goals is to
develop and create new and innovative products and services that
will continue to build MaxCyte’s brand,” said Mr.
Soleymannezhad, EVP of Bioprocessing. “By executing a
compelling marketing strategy that aligns with the Company’s
organizational objectives.”
About MaxCyte At MaxCyte,
we pursue cell engineering excellence to maximize the potential of
cells to improve patients’ lives. We have spent more than 20 years
honing our expertise by building best-in-class platforms,
perfecting the art of the transfection workflow, and venturing
beyond today’s processes to innovate tomorrow’s solutions. Our
ExPERT™ platform, which is based on our Flow Electroporation
technology, has been designed to support the rapidly expanding cell
therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development
through commercialization of next-generation, cell-based medicines.
The ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
MaxCyte Contacts:
US IR
Adviser Gilmartin Group David
Deuchler, CFA +1
415-937-5400 ir@maxcyte.com
US Media
Relations Spectrum Seismic
Collaborative Valerie Enes +1
408-497-8568 valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker Panmure Gordon Emma Earl / Freddy
Crossley Corporate Broking Rupert Dearden +44 (0)20
7886 2500
UK IR
Adviser Consilium Strategic
Communications Mary-Jane Elliott Chris
Welsh +44 (0)203 709 5700 maxcyte@consilium-comms.com
MaxCyte (NASDAQ:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
MaxCyte (NASDAQ:MXCT)
Historical Stock Chart
From May 2023 to May 2024